Weiwei Chen1, Xiaodie Zhou2, Huiyu Li1, Yuchen Yang1, Lu Lu1, Chunyan Zhu1, Rong Fang1, Xiaoyuan Chu1, Shuping Zhou3,*, Qian Sun1,*
Oncology Research, Vol.33, No.8, pp. 2123-2139, 2025, DOI:10.32604/or.2025.063484
- 18 July 2025
Abstract Background: Primary bone marrow diffuse large B-cell lymphoma (PBM-DLBCL) represents an uncommon yet clinically aggressive hematologic malignancy. Despite its significant clinical impact, this entity lacks standardized diagnostic criteria in current WHO classifications. Methods: We performed a retrospective analysis of 55 PBM-DLBCL cases from our institutional database and published literature (2001–2022) to characterize disease features and identify prognostic factors, with particular focus on assessing how different treatment regimens influence therapeutic efficacy and long-term outcomes. Results: The data suggested a potential link between international prognostic index (IPI) scores and poorer survival, albeit without conclusive statistical evidence (p = More >